tbuckley/cabot-search huggingface dataset:
Avascular Necrosis of the Femoral Head in Sickle Cell Disease in Egypt and Oman: A Cross Sectional Study
Authors: Mohsen Saleh Elalfy, Iman Fadhli, Shaimaa Mohammad, Aida Ali, Naema Shibli, Farah Kindi, Sultan Almaskari, Yasser Wali
Journal: Blood (2018)
The Post-Transplant Day 30 Lymphocyte Count Strongly Correlates with Transplanted Cd34 Dose and Is Predictive for Minimal Residual Disease and Mortality in Patients with Cml Undergoing Allogeneic Stem Cell Transplants from Matched Siblings.
Authors: Bipin Savani, Roger Kurlander, Elizabeth Read, Susan Leitman, Nene Nlonda, Neal Young, Richard Childs, Scott Solomon, John Barrett
Journal: Blood (2004)
Functional Assay of VWF Measured by Its Interaction with Platelet GPIb without the Use of Ristocetin.
Authors: Robert R. Montgomery, P. Morateck, P.A. Christopherson, B.C. Kautza, C.A. Miller, B.R. Branchford, V.H. Flood, S.L. Haberichter, D.B. Bellissimo, K.D. Friedman, D.J. Kenny, J.C. Gill
Journal: Blood (2007)
Development of a Risk Score for Prediction of Overall Survival Following Umbilical Cord Blood Transplantation in Acute Leukemia Patients: A Study from the Acute Leukemia Working Party (WP) and Paediatric Disease WP of the European Society for Blood and Marrow Transplantation (EBMT), and Eurocord
Authors: Roni Shouval, Annalisa Ruggeri, Myriam Labopin, Mohamad Mohty, Guillermo Sanz, Gerard Michel, Eefke Petersen, Patrice Chevallier, Amal Al-Seraihy, Noel-Jean Milpied, Cristina Diaz de Heredia Rubio, William Arcese, Didier Blaise, Vanderson Rocha, Joshua Fein, Ron Unger, Frederic Baron, Peter Bader, Eliane Gluckman, Arnon Nagler
Journal: Blood (2016)
Dispermic Chimerism in a Blood Donor with Apparent B3 Blood Group and Mosaic 47, XYY Syndrome.
Authors: Duck Cho, Mark H. Yazer, Myung-Geun Shin, Jong-Hee Shin, Soon-Pal Suh, Jeong-Won Song, Jong Tae Park, Dong-Wook Ryang
Journal: Blood (2005)
Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study
Authors: Stephan Stilgenbauer, Jeffrey A. Jones, Steven Coutre, Anthony R. Mato, Peter Hillmen, Constantine Tam, Anders Osterborg, Tanya Siddiqi, Michael J. Thirman, Richard R. Furman, Osman Ilhan, Michael Keating, Timothy G. Call, Jennifer R. Brown, Yunfeng Li, Karl Eckert, Betty Y. Chang, Danelle F. James, Alvina D. Chu, Michael Hallek, Susan O'Brien
Journal: Blood (2015)
Fusion Protein Ompc-CD154 Inhibits Proliferation and Induces Apoptosis in B-NHL Cell Lines By a Mechanism That Involves MAPK P38 and TRAF2 Activation
Authors: Gerardo Pantoja-Escobar, Laura Romo-Dorantes, Mario Morales-Martinez, Gabriel G Vega, Otoniel Martinez-Maza, Sara Huerta-Yepez, Mario I. Vega
Journal: Blood (2016)
Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment
Authors: Roberto Latagliata, Pasquale Niscola, Maria Antonietta Aloe Spiriti, Ida Carmosino, Laura Cesini, Chiara Sarlo, Annalina Piccioni, Alessia Campagna, Maria Lucia De Luca, Federico Vozella, Melissa Campanelli, Marco Mancini, Massimo Breccia, Giuseppe Avvisati, Agostino Tafuri, Paolo de Fabritiis, Giuliana Alimena, Corrado Girmenia
Journal: Blood (2016)
Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Authors: Thomas Prebet, Steven D. Gore, Zhuoxin Sun, Peter L. Greenberg, Mark Juckett, Lisa Malick, Mitchell R Smith, Elisabeth Paietta, Magdalena Czader, Janice Gabrilove, Harry P Erba, Martin S. Tallman
Journal: Blood (2010)
Retrospective Case Series Study of Hypomethylating Therapy in IPSS Lower-Risk Myelodysplastic Syndrome
Authors: Han-Seung Park, Je-Hwan Lee, Yoo-Jin Kim, Sang Kyun Sohn, Sung-Soo Yoon, Hawk Kim, June-Won Cheong, Won-Sik Lee, Gyeong-Won Lee, Young-Don Joo, Min Kyoung Kim, Yang Soo Kim, Hyeoung-Joon Kim
Journal: Blood (2016)
Recent developments and highlights in food allergy
Authors: Thomas Eiwegger, Lisa Hung, Kristen Ericka San Diego, Liam O'Mahony, Julia Upton
Journal: Allergy (2019)

The achievement of long-lasting, safe treatments for food allergy is dependent on the understanding of the immunological basis of food allergy. Accurate diagnosis is essential for management. In recent years, data from oral food challenges have revealed that routine allergy testing is poor at predicting clinical allergy for tree nuts, almonds in particular. More advanced antigen-based tests including component-resolved diagnostics and epitope reactivity may lead to more accurate diagnosis and selection of therapeutic intervention. Additional diagnostic accuracy may come from cellular tests such as the basophil activation test or mast cell approaches. In the context of clinical trials, cellular tests have revealed specific T-cell and B-cell populations that are more abundant in food-allergic individuals with distinct mechanistic features. Awareness of clinical markers, such as the ability to eat baked forms of milk and egg, continues to inform the understanding of natural tolerance development. Mouse models have allowed for investigation into multiple mechanisms of food allergy including modification of epithelial metabolism, and the induction of regulatory cell subsets and the microbiome. Increasing numbers of children who underwent food immunotherapy enlarged the body of evidence on mechanisms and predictors of treatment success. Experimental immunological markers in conjunction with clinical determinants such as lower age and lower initial specific IgE appear to be of benefit. More research on the optimal dose, preparation, and route of application integrating a high-level safety and efficacy is demanded. Alternatively, biologics blocking TSLP, IL-33, IL-4 and IL-13, or IgE may help to achieve that.
Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
Authors: Alex Pearson, Paula Proszek, Javier Pascual, Charlotte Fribbens, Monee K. Shamsher, Belinda Kingston, Ben O'Leary, Maria T. Herrera-Abreu, Rosalind J. Cutts, Isaac Garcia-Murillas, Hannah Bye, Brian A. Walker, David Gonzalez De Castro, Lina Yuan, Sabri Jamal, Mike Hubank, Elena Lopez-Knowles, Eugene F. Schuster, Mitch Dowsett, Peter Osin, Ashutosh Nerurkar, Marina Parton, Alicia F.C. Okines, Stephen R.D. Johnston, Alistair Ring, Nicholas C. Turner
Journal: Clinical Cancer Research (2019)

Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential to acquire mutations with resistance to treatment and disease progression. To identify potentially targetable mutations in advanced breast cancer, we performed prospective molecular characterization of a cohort of patients with ABC.Biopsies from patients with advanced breast cancer were sequenced with a 41 genes targeted panel in the ABC Biopsy (ABC-Bio) study. Blood samples were collected at disease progression for circulating tumor DNA (ctDNA) analysis, along with matched primary tumor to assess for acquisition in ABC in a subset of patients.We sequenced 210 ABC samples, demonstrating enrichment compared with primary disease for potentially targetable mutations in HER2 (in 6.19% of samples), AKT1 (7.14%), and NF1 (8.10%). Of these enriched mutations, we show that NF1 mutations were frequently acquired in ABC, not present in the original primary disease. In ER-positive cancer cell line models, loss of NF1 resulted in endocrine therapy resistance, through both ER-dependent and -independent mechanisms. NF1 loss promoted ER-independent cyclin D1 expression, which could be therapeutically targeted with CDK4/6 inhibitors in vitro. Patients with NF1 mutations detected in baseline circulating tumor DNA had a good outcome on the CDK4/6 inhibitor palbociclib and fulvestrant.Our research identifies multiple therapeutic opportunities for advanced breast cancer and identifies the previously underappreciated acquisition of NF1 mutations.
Copy Number Alterations of PAX5, CDKN2A/B Genes Rather Than IKZF1 gene Are Associated with Pathogenesis of Childhood ALL in Korean Assessed by Multiplex Ligation-Dependent Probe Amplification
Authors: Dong Kyun Han, Li Yu, Huong Thi Thanh Tran, Hee Nam Kim, Il Kwon Lee, Hee Jo Baek, Sul Hee Bae, Hyeoung Joon Kim, Hoon Kook, Tai Ju Hwang
Journal: Blood (2011)
Drug selection by Narrative approach in patients with advanced gastric cancer -Paclitaxel or nab-Paclitaxel?-
Authors: Tomono Kawase, Hiroshi Imamura, Masashi Hirota, Hirotsugu Nagase, Shingo Noura, Tsukasa Tanida, Kouzou Noguchi, Kazuki Ooshima, Kenzou Akagi, Takushi Iwazawa, Keizou Douno
Journal: Annals of Oncology (2019)
Outcomes for B-Precursor Patients in Legacy Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.
Authors: Paul S. Gaynon, Bruce C. Camitta, Yousif Matloub, Paul L. Martin, Naomi Winick, Nita L. Seibel, W. Paul Bowman, Harland N. Sather, Meenakshi Devidas, Stephen Hunger, William L. Carroll
Journal: Blood (2007)
Galectin-3 and Myocardial Fibrosis By Cardiac Magnetic Resonance in Thalassaemia Major
Authors: Paolo Ricchi, Antonella Meloni, Tiziana Di Matola, Anna Spasiano, Aldo Filosa, Silvia Costantini, Luigi Atripaldi, Salvatore Esposito, Patrizia Cinque, Lucia De Franceschi, Alessia Pepe
Journal: Blood (2016)
CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate
Authors: Daniel W. Sherbenou, Blake T. Aftab, Yang Su, Christopher R. Behrens, Arun P. Wiita, Aaron C. Logan, Diego Acosta-Alvear, Byron C. Hann, Peter Walter, Xiaobo Wu, John P. Atkinson, Jeffrey L. Wolf, Thomas G. Martin, Bin Liu
Journal: Blood (2016)
Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles
Authors: Catherine C. Coombs, Ahmet Zehir, Sean Devlin, Ashwin Kishtagari, David M. Hyman, David Solit, Mark Robson, Jose Baselga, Maria Arcila, Martin S. Tallman, Ross L. Levine, Michael Berger
Journal: Blood (2016)
DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival
Authors: Seyedmehdi Shojaee, Maike Buchner, Huimin Geng, Ari Melnick, Sigal Gery, Jeffery Molkentin, Phillip Koeffler, Markus Muschen
Journal: Blood (2011)
Abstract 16596: Dominant Mouse Mutagenesis Screen Unveils a Complex Genetic Architecture for Congenital Heart Disease
Authors: Michael Wang, Tuantuan Tan, Sara Hildebrand, Abha Bais, Sebastian Ho, Yiming Wang, Daniel Sonnenberg, Manisha Kukkillaya, Caleb Radomile, Lauren Meyer, William Devine, Laura Reinholdt, Bruce Beutler, Yijen Wu, Cecilia Lo
Journal: Circulation (2018)

Introduction: Human studies show congenital heart disease (CHD) has a complex non-Mendelian genetic etiology. We previously conducted a recessive N-ethyl-N-nitrosourea (ENU) mouse mutagenesis screen using fetal ultrasound and recovered over 150 recessive mutations causing CHD. In the present study, we conducted a sensitized screen with driver mutations to recover dominant mutations causing CHD. We hypothesize this dominant screen can help to elucidate the complex genetic architecture of CHD. Methods: G1 males with heterozygous ENU induced mutations were mated to females harboring heterozygous “driver” mutation in Kif7, Anks6, or Sap130 that can cause CHD when homozygous. The resulting G2 offspring were screened for CHD by fetal ultrasound. Mutations in G1 males were identified by whole exome sequencing and the G2 offspring were genotyped using Ion Torrent sequencing. Linkage analysis was conducted to identify the CHD causing mutation. Results: We found 9.3% of the G1 pedigrees (n=551) yielded CHD mutants, similar to the 8.2% observed in the previous recessive screen. However, only 2.5 mutants were recovered per line vs. 4.5 in the recessive screen despite having screened similar number of embryos, supporting non-Mendelian genetics in the dominant screen. Genotype-phenotype analysis revealed only 32%, 45%, and 55% of the CHD mutants recovered carried the Kif7, Anks6, or Sap130 driver mutations, respectively, suggesting the driver mutations are not required for CHD pathogenesis. For mouse line 4142 with DORV/OA, we identified a heterozygous p21/Rac-activated kinase 2 ( Pak2) mutation as disease causing (p=4.8e-12). CHD penetrance was 83% among Pak2 +/m embryos. Among surviving 4142 G2 offspring, only 14% have the Pak2 mutation vs. 50% expected. We observed 75% of the surviving Pak2 mutant mice also carry a mutation in Zbtb2, a gene identified to regulate p21, suggesting this may act as a protective modifier. Conclusion: We showed the feasibility of using mouse mutagenesis to recover dominant mutations causing CHD, and showed for the first time a role for Pak2 in CHD. These findings demonstrate that the genetic diversity created by ENU mutagenesis can provide the genomic context to investigate the complex genetics and genetic architecture of CHD.
The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set
Authors: Rainer Claus, Amy S. Ruppert, David M. Lucas, Manuela Zucknick, Laura Z. Rassenti, Andrew Greaves, Donna S. Neuberg, William G. Wierda, Michael J. Keating, Jennifer R. Brown, John G Gribben, Kanti R. Rai, Michael R. Grever, Neil E. Kay, Thomas J. Kipps, Christoph Plass, John C. Byrd
Journal: Blood (2012)
Incompatibilities of HA-1 and CD62L Polymorphic Adhesion Molecule Induce Graft-versus-Leukemia Effect Rather Than GVHD Resulted in Long-Term Survival in HLA Identical Myeloablative Stem Cell Transplantation.
Authors: Takamasa Katagiri, Shintaro Shiobara, Tatsuo Furukawa, Jyunichi Tsukada, Shinji Nakao, Miki Wakano, Eriko Muranaka, Mine Harada
Journal: Blood (2004)
Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treated with Modified Augmented Berlin-Frankfurt-Muenster (ABFM) Therapy
Authors: Michael E. Rytting, Deborah A. Thomas, Elias Jabbour, Anna R.K. Franklin, Gautam Borthakur, Stefan Faderl, Kurt Schroeder, Farhad Ravandi, Rebecca Garris, Susan o'Brien, Hagop M. Kantarjian
Journal: Blood (2011)
Assesment of Frailty Scores Validating Fitness of Elderly AML Patients for Intensive Chemotherapy: A Single Centre Study
Authors: Semra Aydin, Marco Franzino, Chiara Frairia, Ernesta Audisio, Stefano D'Ardia, Irene Urbino, Alessandro Busca, Chiara Maria Dellacasa, Giorgia Iovino, Andrea Evangelista, Giovannino Ciccone, Umberto Vitolo
Journal: Blood (2018)
Superior Survival after Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Diffuse Large B-Cell Lymphoma (DLBCL) Not Explained by Differences in Chemosensitivity.
Authors: Brandon Hayes-Lattin, Jeanette Carreras, Mei-Jie Zhang, Koen van Besien, Julie M. Vose, Hillard M. Lazarus, J. Douglas Rizzo, Parameswaran Hari
Journal: Blood (2006)
A New Murine Model of Immune Thrombocytopenia: Evidence of Both Antibody- and CD8+ T Cell-Mediated Platelet Destruction.
Authors: Leola Chow, Heyu Ni, Michael Kim, Edwin R. Speck, Rukhsana Aslam, Pingguo Chen, John Freedman, John W. Semple
Journal: Blood (2007)
A Multivariate Clinical and Economic Model for Predicting Risk-Based Costs of Care for Acute Leukemia (AL) Patients (Pts) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Authors: Joseph C. Alvarnas, Guido Marcucci, Ann Vanderplas, Eileen P. Smith, Joyce L. Murata-Collins, Alexandra M. Levine, Joyce Niland, Joycelynne Palmer, Tsai Ni-Chun, Rebecca Ottesen, Michael Rabin, Zara Dzagikian, Shery Azimi, Joseph Rosenthal, Harlan Levine, Stephen J. Forman
Journal: Blood (2016)
The Kids-DOTT Trial: Novel Aspects of the ‘Parallel Cohort RCT‘ Design and Its Application to the Investigation of Duration of Anticoagulant Therapy for Pediatric Venous Thromboembolism.
Authors: Neil A. Goldenberg, Mark Tripputi, Mark A. Crowther, Thomas C. Abshire, Donna M. DiMichele, Marilyn J. Manco-Johnson, William R Hiatt
Journal: Blood (2009)
Oral Deferasirox (Exjade®, ICL670) Is Effective, with a Clinically Manageable Safety Profile, in Pediatric β-Thalassemia Patients with High Iron Burden.
Authors: Ali Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Ulrike Kriemler-Krahn, Dietrich Pfluger, Dominik Hadler, Amal El-Beshlawy
Journal: Blood (2007)
Allogeneic Stem Cell Transplantation Using a Reduced Intensity Conditioning (RIC) Regimen Has the Capacity To Produce Durable Remissions and Long Term Disease-Free Survival in Patients with High Risk Acute Myeloid Leukemia (AML).
Authors: S. Tauro, S. Mackinnon, K. Peggs, G. Begum, P. Mahendra, G. Cook, J. Marsh, D. Milligan, A. Goldstone, A. Hunter, A. Khwaja, R. Chopra, T. Littlewood, A. Peniket, A. Parker, G. Jackson, G. Hale, M. Cook, N. Russell, C. Craddock
Journal: Blood (2005)
Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3.
Authors: Luis Fayad, Michael Overman, Barbara Pro, Peter McLaughlin, Felipe Samaniego, Anas Younes, Jorge Enrique Romaguera, F.B. Hagemeister, Larry Kwak, Maria Alma Rodriguez
Journal: Blood (2006)
Inhibition of Histone Deacetylase Activity Compromises Homologous Recombination Repair and Increases Sensitivity of Chemo-Resistant Chronic Lymphocytic Leukemia Cells to Olaparib
Authors: Angelo Agathanggelou, David Cartwright, Helen Parry, Guy Pratt, Paul Moss, Tatjana Stankovic
Journal: Blood (2012)
Global Gene Expression Analysis Demonstrates that Transforming Growth Factor β1 (TGF-β1) Signals Exclusively through Receptor Complexes Involving TGF-β Receptor I and Identifies Numerous Targets of TGF-β Signaling.
Authors: Goran Karlsson, Yingchun Liu, Marie-José Goumans, Jonas Larsson, Ju-Seog Lee, Snorri S. Thorgeirsson, Markus Ringnér, Stefan Karlsson
Journal: Blood (2004)
ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG
Authors: Francesco Lo-Coco, Giuseppe Avvisati, Sonia Maria Orlando, Felicetto Ferrara, Marco Vignetti, Paola Fazi, Eros Di Bona, Giorgina Specchia, Simona Sica, Mariadomenica Divona, Alessandro Levis, Walter Fiedler, Elisa Cerqui, Massimo Breccia, Giuseppe Fioritoni, Helmut R Salih, Christian H. Brandts, Enrica Morra, Marie von Lilienfeld-Toal, Bernd Hertenstein, Mohammed Wattad, Michael Lubbert, Matthias Hänel, Norbert Schmitz, Hartmut Link, Maria Grazia Kropp, Alessandro Rambaldi, Giorgio La Nasa, Mario Luppi, Fabio Ciceri, Michaela Sauer, Hartmut Dohner, Arnold Ganser, Franco Mandelli, Gerhard Ehninger, Sergio Amadori, Christian Thiede, Richard F Schlenk, Uwe Platzbecker
Journal: Blood (2012)
Central Nervous System Invasion in Multiple Myeloma: A Nationwide Survey of 75 Patients in Japan
Authors: Takeshi Yamashita, Hiroyuki Takamatsu, Koji Kawamura, Kazutaka Sunami, Shotaro Hagiwara, Mitsuhiro Itagaki, Tsutomu Takahashi, Tadakazu Kondo, Takashi Ikeda, Kyoko Watakabe-Inamoto, Hiroshi Handa, Yoshitaka Imaizumi, Junya Kuroda, Jun Murakami, Yuichi Nakamura, Hideyuki Nakazawa, Shuji Ozaki, Shinji Nakao, Kensei Tobinai, Shinsuke Iida
Journal: Blood (2016)
CD20 Mutations at the Rituximab Binding Site Are Rare and Are Not a Significant Cause of R-CHOP Resistance in Patients with De Novo Diffuse Large B-Cell Lymphoma.
Authors: Nathalie A. Johnson, Steven Leach, Laurie Sehn, Joseph M. Connors, Angela Brooks-Wilson, Randy D. Gascoyne
Journal: Blood (2007)
Functional Defects of T Cells of NHL Patients after Different Chemotherapy Regimens Activated By CD19/CD3 Tetravalent Bispecific TandAb® AFM11
Authors: Johannes Duell, Dragana Slavkovic, Margarete Karg, Uwe Reusch, Florian Eisele, Jens-Peter Marschner, Hermann Einsele, Martin Treder, Max S. Topp
Journal: Blood (2016)
Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedures
Authors: Antoine Rauch, Eric Van Belle, André Vincentelli, Paulette Legendre, Emmanuelle Jeanpierre, Christopher Hurt, Carlo Banfi, Claudine Caron, Francis Juthier, Ahmed Elkalioubie, Natacha Rousse, Delphine Corseaux, Christophe Zawadzki, Giulia Chinetti, Brigitte Jude, Jenny Goudemand, Bart Staels, Peter J. Lenting, Sophie Susen
Journal: Blood (2014)
Latium (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPN
Authors: Marianna De Muro, Ambra Di Veroli, Marco Montanaro, Roberto Latagliata, Cristina Santoro, Massimo Breccia, Michele Cedrone, Barbara Anaclerico, Malgorzata Monika Trawinska, Elisabetta Abruzzese, Annamaria Rauco, Sabrina Leonetti Crescenzi, Nicoletta Villivà, Giuseppe Cimino, Atelda Romano, Antonio Spadea, Elena Rossi, Valerio De Stefano, Luca Petriccione, Ada D'Addosio, Francesco Buccisano, Roberto Ricci, Giuliana Alimena, Giuseppe Avvisati, Alessandro Andriani
Journal: Blood (2016)
NFATc1 Is Transcriptionally Activated in Chronic Lymphocytic Leukemia (CLL) By Promotor DNA-Hypomethylation Which Correlates with in-Vitro Vulnerability to Calcineurin Inhibitors
Authors: Christine Wolf, Katharina Filarsky, Angela Garding, Rainer Claus, Christopher C Oakes, Irina Idler, Christoph Plass, Peter Lichter, Hartmut Doehner, Stephan Stilgenbauer, Daniel Mertens
Journal: Blood (2014)
A Regulatory Network Between Notch and AKT Signaling Pathways Differentially Controls Megakaryocyte Development From Hematopoietic Stem or Committed Progenitor Cells.
Authors: Melanie G Cornejo, Stephen M Sykes, Cristina Lo Celso, Zuzana Tothova, Jon Aster, Ronald A DePinho, David T Scadden, D. Gary Gilliland, Thomas Mercher
Journal: Blood (2009)
Association of gastric acid suppression with efficacy of immune checkpoint inhibitors (ICIs) in advanced cancer patients
Authors: Naoki Izawa, Hisae Shiokawa, Risa Onuki, Koki Hamaji, Naoki Furuya, Hiroyuki Ohashi, Tomohiro Nishi, Shigeru Kasugai, Hiroyuki Arai, Ayako Doi, Yoshiki Horie, Mami Hirakawa, Takuro Mizukami, Takashi Ogura, Takashi Tsuda, Yu Sunakawa, Takako Nakajima
Journal: Annals of Oncology (2019)
Activation Status of Integrin αIIbβ3 in Essential Thrombocythemia with Calreticulin Mutation
Authors: Jun Yamanouchi, Takaaki Hato, Etsuko Matsubara, Taichi Azuma, Hideyuki Nakanishi, Hiroshi Fujiwara, Yoshihiro Yakushijin, Masaki Yasukawa
Journal: Blood (2014)
Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients with Relapsed Chronic Lymphocytic Leukemia
Authors: Ekaterina Kim, Lillian Werner, Michael J Keating, William G. Wierda, Alessandra Ferrajoli, Zeev Estrov, Gracy Zacharian, Thomas J. Kipps, Hagop M. Kantarjian, Donna Neuberg, Susan O'Brien, Jan A. Burger
Journal: Blood (2014)
The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)
Authors: Michael Roost Clausen, Sirpa Leppa, Peter de Nully Brown, Jette Soenderskov Goerloev, Michael Panny, Wolfgang Willenbacher, Ida Blok Sillesen, Erik Segel, Hans Bentzen, Michael Thorsgaard, Elisa Jacobsen Pulczynski, Peter Kamper, Lars C. Gormsen, Julie Mortensen, Grethe Lauritzsen, Thomas Relander, Francesco d'Amore
Journal: Blood (2016)